ArticleVirchows Archiv : an international journal of pathology2003
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Article in Virchows Archiv : an international journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis.World journal of surgery · 2018Pooled it
- ERBB2 as a prognostic biomarker correlates with immune infiltrates in papillary thyroid cancer.Frontiers in genetics · 2022Article
- Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.Cancers · 2019Review
- HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin.International journal of molecular sciences · 2016Article
- Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study.Journal of breast cancer · 2015Article
- Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer.Molecular and clinical oncology · 2014Article
- Molecular pathways associated with aggressiveness of papillary thyroid cancer.Current genomics · 2014Article
- Prognostic biomarkers in thyroid cancer.Virchows Archiv : an international journal of pathology · 2014Review
- Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer.American journal of cancer research · 2014Article
- Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.Medical oncology (Northwood, London, England) · 2012Article
- EGF and TGF-β1 Effects on Thyroid Function.Journal of thyroid research · 2011Article
- S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma.British journal of cancer · 2005Article
- Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels.Pharmaceutical research · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the prognostic value of Her2/neu expression in differentiated thyroid carcinomas 103 patients were retrospectively investigated. All of them received surgical and an identical follow-up treatment. The patients with papillary and follicular thyroid cancer were further separated into two groups concerning their clinical development, including one group without distant metastasis (follow-up of minimum 8 years). The second group presented with distant metastases as a sign of an aggressive behaviour. Her2/neu was immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using c-erbB-2/Her-2/neu oncoprotein Ab-17 monoclonal antibody (mAb). In statistical analysis using the Mann-Whitney U-test and chi(2) test, Her2/neu protein overexpression was significantly correlated with prognosis. Both tumour entities without distant metastases showed significantly less cytoplasmic immunostaining than patients with development of metastases. Concerning the clinical outcome, Her2/neu overexpression may be regarded as a prognostic factor in differentiated thyroid carcinomas. Moreover, in addition to standard radio-iodine elimination therapy, application of Herceptin could lead to new successful therapeutic concepts for a number of patients with progressive thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.